The efficacy of TKIs for CML is directly dependent on their ability to inhibit the ABL1 kinase domain of the BCR-ABL1 fusion protein and inhibit unregulated cell proliferation. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.